The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Adverse Events Associated with Testosterone Administration
Open accessAbstract
BACKGROUND: Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied. METHODS: Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group. RESULTS: A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load. CONCLUSIONS: In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy. (ClinicalTrials.gov number, NCT00240981.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence consistently shows that untreated low testosterone levels are associated with an increased risk of MACE”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, T supplementation is not without risk and could potentially be harmful concerning cardiovascular risk in the elderly [248].”
From Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology (2022) · cites this paper as [248]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have previously reported that testosterone levels are linked to a variety of conditions and diseases, such as cardiovascular disease, type-2 diabetes, the metabolic syndrome, erectile dysfunction, depression, obesity, stroke and osteoporosis. 1-7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“studies that measure cardiovascular benefit or harm in men on testosterone therapy have returned inconsistent and controversial results.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“the current scientific literature does not definitively demonstrate that testosterone therapy increases the risk of MACE.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“and that testosterone administration can increase the risk of cardiovascular adverse events as well. 7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
In the citing paper
“Low vitamin D levels have been associated with frailty (133)”
From Frailty in elderly people (2013) · cites this paper as [133]
In the citing paper
“Additionally, testosterone replacement is not without potential risks, including increased respiratory disorders (eg, cough, shortness of breath, asthma or chronic obstructive pulmonary disease (COPD) exacerbation, sleep apnoea) and skin and subcutaneous tissue disorders (eg, application site reactions, itching, erythema, foot ulcers, and increased hair growth).84”
From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [84]
In the citing paper
“preventing an age-related decline in hormones by exogenous replacement is associated with increased risk for adverse effects in older adults.11-13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Unfortunately, hormone replacement therapy is not a panacea, as it often results in various adverse events which outweigh its potential health benefits.”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Some of the risks associated with T therapy include exacerbation of prostate cancer, cardiovascular-related events, hepatotoxicity, erythrocytosis, sleep apnea, and dermatological issues.12, 13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Serum hepcidin was measured by enzyme-linked immunosorbent assay (Intrinsic Life Sciences) with sensitivity of 5 ng/mL, interassay coefficient of variation 12%, and range 29-254 ng/ mL in men (12,15).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We have reported that administration of supraphysiologic doses of testosterone in healthy men suppresses the iron regulatory peptide hepcidin while EPO levels remained unchanged after 20 weeks of treatment (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We also show that testosterone administration is associated with lower hepcidin levels in older men with mobility limitation and high burden of chronic diseases, confirming our previous observations in healthy younger and older men and demonstrating a similar magnitude of hepcidin suppression (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“It can be concluded that the effects of testosterone on muscle strength are demonstrable after 12–20 weeks and that depending on the achieved testosterone levels, the maximum effects are attained after 6 or 12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“Another study using high doses of testosterone gel (starting dose 100 mg/day with possible up-titration to 150 mg/day) observed significant increases in leg press strength, chest press strength, and stair climbing power with a load within 6 months (16).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability
Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive, M. E., & Wallace, R. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320902 · Cited by 4,083
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationFried, L. P. (1998) · JAMA · doi:10.1001/jama.279.8.585 · Cited by 1,107
Newman, A. B., Simonsick, E. M., Naydeck, B. L., Boudreau, R. M., Kritchevsky, S. B., Nevitt, M. C., Pahor, M., Satterfield, S., Brach, J. S., Studenski, S. A., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2018 · Cited by 934
Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R., Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., & Ross, C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.6.3988 · Cited by 920
Associations of Subclinical Cardiovascular Disease With Frailty
Newman, A. B., Gottdiener, J. S., McBurnie, M. A., Hirsch, C. H., Kop, W. J., Tracy, R. P., Walston, J. D., & Fried, L. P. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.3.m158 · Cited by 813
Predictors of skeletal muscle mass in elderly men and women
Baumgartner, R. N., Waters, D. L., Gallagher, D., Morley, J. E., & Garry, P. J. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00130-4 · Cited by 809
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jc.82.6.1661 · DOI
Cited by
Sorted by citations
Items 401–500 of 1,000
Yu, S., Umapathysivam, K., & Visvanathan, R. (2014) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000018 · Cited by 44
Yeap, B. B., Page, S. T., & Grossmann, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30416-3 · Cited by 43
Obesity, Body Composition, and Sex Hormones: Implications for Cardiovascular Risk
Singh, P., Covassin, N., Marlatt, K. L., Gadde, K. M., & Heymsfield, S. B. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210014 · Cited by 44
Transgender patients and the role of the coagulation clinician
Connors, J. M., & Middeldorp, S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14626 · Cited by 42
Testosterone therapy and cardiovascular diseases
Cittadini, A., Isidori, A. M., & Salzano, A. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab241 · Cited by 42
Braun, S. R. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6892 · Cited by 42
Chan, Y. X., Knuiman, M. W., Hung, J., Divitini, M., Beilby, J. P., Handelsman, D. J., Beilin, J., McQuillan, B., & Yeap, B. B. (2016) · Clinical Endocrinology · doi:10.1111/cen.13089 · Cited by 42
Cardiovascular disease in transgendered people: A review of the literature and discussion of risk
Seal, L. (2019) · JRSM Cardiovascular Disease · doi:10.1177/2048004019880745 · Cited by 44
Nyquist, M. D., Ang, L. S., Corella, A. N., Coleman, I. M., Meers, M. P., Christiani, A. J., Pierce, C., Janssens, D. H., Meade, H. E., Bose, A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146777 · Cited by 42
Handelsman, D. J. (2017) · JAMA · doi:10.1001/jama.2017.0129 · Cited by 42
Testosterone replacement attenuates mitochondrial damage in a rat model of myocardial infarction
Wang, F., Yang, J., Sun, J., Dong, Y., Zhao, H., Shi, H., & Fu, L. (2015) · Journal of Endocrinology · doi:10.1530/joe-14-0638 · Cited by 41
Plasma Total Testosterone and Incident Cardiovascular Events in Hypertensive Patients
Vlachopoulos, C., Ioakeimidis, N., Terentes-Printzios, D. G., Aznaouridis, K., Rokkas, K., Aggelis, A., Synodinos, A., Lazaros, G. A., & Stefanadis, C. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hps056 · Cited by 41
Glueck, C. J., Richardson-Royer, C., Schultz, R., Burger, T., Bowe, D., Padda, J., & Wang, P. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029613499819 · Cited by 41
Anabolic–androgenic steroid use among Brazilian women: an exploratory investigation
Abrahin, O., Souza, N. S. F., de Sousa, E. C., Santos, A. M., & Bahrke, M. S. (2016) · Journal of Substance Use · doi:10.1080/14659891.2016.1179806 · Cited by 41
Cole, A. P., Hanske, J., Jiang, W., Kwon, N. K., Lipsitz, S. R., Kathrins, M. N., Learn, P. A., Sun, M., Haider, A. H., Basaria, S. S., et al. (2018) · British Journal of Urology · doi:10.1111/bju.14149 · Cited by 42
Self-citationTestosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events
Glueck, C. J., Goldenberg, N., & Wang, P. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm8010011 · Cited by 41
Frailty and HIV: Moving from Characterization to Intervention
Erlandson, K. M., & Piggott, D. A. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00554-1 · Cited by 44
Birzniece, V., Meinhardt, U. J., Umpleby, A. M., Handelsman, D. J., & Ho, K. K. Y. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2521 · Cited by 41
Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions
Comninos, A. N., Demetriou, L., Wall, M. B., Shah, A., Clarke, S. A., Narayanaswamy, S., Nesbitt, A., Izzi‐Engbeaya, C. N., Prague, J., Abbara, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121958 · Cited by 41
Testosterone Deficiency and Replacement in Older Men
Bremner, W. J. (2010) · New England Journal of Medicine · doi:10.1056/nejme1006197 · Cited by 41
An update on testosterone, HDL and cardiovascular risk in men
Thirumalai, A., Rubinow, K. B., & Page, S. T. (2015) · Clinical Lipidology · doi:10.2217/clp.15.10 · Cited by 41
Testosterone, thrombophilia, thrombosis
Freedman, J., Glueck, C. J., Prince, M., Riaz, R., & Wang, P. (2015) · Translational research · doi:10.1016/j.trsl.2014.12.003 · Cited by 41
Canoy, D., Barber, T. M., Pouta, A., Hartikainen, A. L., McCarthy, M. I., Franks, S., Järvelin, M., Tapanainen, J. S., Ruokonen, A., Huhtaniemi, I. T., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1046 · Cited by 40
Lerchbaum, E., Pilz, S., Boehm, B. O., Grammer, T. B., Obermayer‐Pietsch, B., & März, W. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04371.x · Cited by 40
Gagliano‐Jucá, T., Pencina, K. M., Guo, W., Li, Z., Huang, G. T.-W., Basaria, S. S., & Bhasin, S. (2020) · Andrology · doi:10.1111/andr.12834 · Cited by 40
Self-citationQu, M., Feng, C., Wang, X., Gu, Y., Shang, X., Zhou, Y., Xiong, C., & Li, H. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019559 · Cited by 40
Monastra, G., Vazquez-Levin, M. H., Espinola, M. S. B., Bilotta, G., Laganà, A. S., & Unfer, V. (2021) · Basic and Clinical Andrology · doi:10.1186/s12610-021-00131-x · Cited by 41
Caveat Emptor: Does Testosterone Treatment Reduce Mortality in Men?
Wu, F. C. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1977 · Cited by 40
Swerdloff, R. S., Pak, Y., Wang, C., Liu, P. Y., Bhasin, S., Gill, T. M., Matsumoto, A. M., Pahor, M., Surampudi, P., & Snyder, P. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1542 · Cited by 39
Self-citationPatterns of testosterone prescription overuse
Jasuja, G. K., Bhasin, S., & Rose, A. J. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000336 · Cited by 39
Self-citationCardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms
Tivesten, Å., Pinthus, J. H., Clarke, N. W., Duivenvoorden, W., & Nilsson, J. Å. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.05.030 · Cited by 39
Saeed, A., Vaught, G. M., Gavardinas, K., Matthews, D. P., Green, J. E., García‐Losada, P., Bullock, H. A., Calvert, N. A., Patel, N. J., Sweetana, S. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01168 · Cited by 39
Otzel, D. M., Lee, J., Ye, F., Borst, S. E., & Yarrow, J. F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061701 · Cited by 40
Tint, A. N., Hoermann, R., Wong, H., Ekinci, E. I., MacIsaac, R. J., Jerums, G., Zajac, J. D., & Grossmann, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0672 · Cited by 38
Gencer, B., & Mach, F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv439 · Cited by 38
Androgens and cardiovascular disease in women and men
Armeni, E., & Lambrinoudaki, I. V. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.07.010 · Cited by 39
Chasland, L. C., Yeap, B. B., Maiorana, A., Chan, Y. X., Maslen, B. A., Cooke, B. R., Dembo, L. G., Naylor, L. H., & GREEN, D. J. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00010.2021 · Cited by 39
Molecular Targets of Androgen Signaling that Characterize Skeletal Muscle Recovery and Regeneration
MacKrell, J. G., Yaden, B. C., Bullock, H. A., Chen, K., Shetler, P. K., Bryant, H. U., & Krishnan, V. (2015) · Nuclear Receptor Signaling · doi:10.1621/nrs.13005 · Cited by 38
Sönmez, A., Haymana, C., Bolu, E., Aydoğdu, A., Tapan, S., Serdar, M. A., Altun, B., Barçın, C., Taşlıpınar, A., Meriç, C., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0951 · Cited by 38
Independent Effects of Testosterone on Lipid Oxidation and VLDL-TG Production
Høst, C., Gormsen, L. C., Christensen, B., Jessen, N., Hougaard, D. M., Christiansen, J. S., Pedersen, S. B., Jensen, M. D., Nielsen, S., & Gravholt, C. H. (2013) · Diabetes · doi:10.2337/db12-0440 · Cited by 37
Saad, F. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2354 · Cited by 37
Systematic Literature Review of the Epidemiology of Nongenetic Forms of Hypogonadism in Adult Males
Zarotsky, V., Huang, M., Carman, W. J., Morgentaler, A., Singhal, P. K., Coffin, D., & Jones, T. H. (2014) · Journal of Hormones · doi:10.1155/2014/190347 · Cited by 38
Haring, R., Travison, T. G., Bhasin, S., Vasan, R. S., Wallaschofski, H., Davda, M. N., Coviello, A. D., & Murabito, J. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1068 · Cited by 37
Self-citationBhasin, S., Krishnan, V., Storer, T. W., Steiner, M., & Dobs, A. S. (2023) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glad027 · Cited by 36
Self-citationYuki, A., Ando, F., Otsuka, R., & Shimokata, H. (2014) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12278 · Cited by 36
Chan, Y. X., Knuiman, M. W., Hung, J., Divitini, M., Handelsman, D. J., Beilby, J. P., McQuillan, B., & Yeap, B. B. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0196 · Cited by 36
Rubinow, K. B., Vaisar, T., Tang, C., Matsumoto, A. M., Heinecke, J. W., & Page, S. T. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p026005 · Cited by 37
Nightingale, T. E., Moore, P. D., Harman, J., Khalil, R. E., Gill, R. S., Castillo, T. A., Adler, R. A., & Gorgey, A. S. (2017) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2017.1357917 · Cited by 37
Testosterone Deficiency, Weakness, and Multimorbidity in Men
Peterson, M. D., Belakovskiy, A., McGrath, R. P., & Yarrow, J. F. (2018) · Scientific Reports · doi:10.1038/s41598-018-24347-6 · Cited by 36
Harada, N. (2018) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2018.1490172 · Cited by 37
Vartolomei, M. D., Kimura, S., Vartolomei, L., & Shariat, S. F. (2018) · European Urology Focus · doi:10.1016/j.euf.2018.07.006 · Cited by 37
Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men
Izzi‐Engbeaya, C. N., Jones, S., Crustna, Y., Machenahalli, P. C., Papadopoulou, D., Modi, M., Panayi, C., Starikova, J., Eng, P. C., Phylactou, M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa072 · Cited by 36
Improving clinical outcomes through attention to sex and hormones in research
Mielke, M. M., & Miller, V. M. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00531-z · Cited by 40
Therapies for diabetic dyslipidaemia
Bell, D. S. H., Badarin, F. J. A., & O’Keefe, J. H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01342.x · Cited by 36
Multiple sclerosis in men: management considerations
Bove, R. M., McHenry, A., Hellwig, K., Houtchens, M. K., Razaz, N., Smyth, P. S., Tremlett, H. L., Sadovnick, A. D., & Rintell, D. J. (2016) · Journal of Neurology · doi:10.1007/s00415-015-8005-z · Cited by 37
Selection and characterization of DNA aptamers against the steroid testosterone
Skouridou, V., Jauset‐Rubio, M., Ballester, P., Bashammakh, A. S., El-Shahawi, M. S., Al-Youbi, A. O., & O’Sullivan, C. K. (2017) · Microchimica Acta · doi:10.1007/s00604-017-2136-0 · Cited by 36
Zaid, M. I. A., Gathirua‐Mwangi, W. G., Fung, C., Monahan, P. O., El-Charif, O., Williams, A. M., Feldman, D. R., Hamilton, R. J., Vaughn, D. J., Beard, C. J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7046 · Cited by 35
Oni, O. A., Dehkordi, S. H. H., Jazayeri, M., Sharma, R., Sharma, M., Masoomi, R., Sharma, R., Gupta, K., & Barua, R. S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.07.019 · Cited by 35
Zhang, Z., Kang, D., & Li, H. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0509-6 · Cited by 35
Irwig, M. S., Fleseriu, M., Jonklaas, J., Tritos, N. A., Yuen, K. C. J., Correa, R. R., Elhomsy, G. C., Garla, V. V., Jasim, S., Soe, K. K., et al. (2020) · Endocrine Practice · doi:10.4158/ps-2019-0540 · Cited by 35
Kaminetsky, J. C., Moclair, B., Hemani, M. L., & Sand, M. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02196.x · Cited by 35
Shoskes, D. A., Kerr, H., Askar, M. Z., Goldfarb, D. A., & Schold, J. D. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.03.102 · Cited by 35
Storer, T. W., Bhasin, S., Travison, T. G., Pencina, K. M., Miciek, R., McKinnon, J., & Basaria, S. S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4333 · Cited by 35
Self-citationOsteoporosis in Men: Epidemiology, Pathophysiology, and Clinical Characterization
ORWOLL, E. S., & KLEIN, R. F. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50044-6 · Cited by 35
Taylor, S. R., Meadowcraft, L., & Williamson, B. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1623 · Cited by 34
Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Giagulli, V. A., Guastamacchia, E., Pergola, G. D., Iacoviello, M., & Triggiani, V. (2013) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530311313010011 · Cited by 34
The Impact of Drug Reimbursement Policy on Rates of Testosterone Replacement Therapy among Older Men
Piszczek, J., Mamdani, M., Antoniou, T., Juurlink, D. N., & Gomes, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098003 · Cited by 34
Gandaglia, G., Briganti, A., Montorsi, P., Mottrie, A., Salonia, A., & Montorsi, F. (2016) · European Urology · doi:10.1016/j.eururo.2016.01.054 · Cited by 34
Common Clinical Sequelae of Aging
Minaker, K. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00024-5 · Cited by 34
Laurent, M. R., Jardí, F., Dubois, V., Schollaert, D., Khalil, R., Gielen, E., Carmeliet, G., Claessens, F., & Vanderschueren, D. (2016) · Bone · doi:10.1016/j.bone.2016.09.011 · Cited by 34
Androgen-Regulated Cardiac Metabolism in Aging Men
Barrientos, G. C., Llanos, P., Basualto-Alarcón, C., & Estrada, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00316 · Cited by 35
Endocrine system dysfunction and chronic heart failure: a clinical perspective
Lisco, G., Giagulli, V. A., Iovino, M., Zupo, R., Guastamacchia, E., Pergola, G. D., Iacoviello, M., & Triggiani, V. (2021) · Endocrine · doi:10.1007/s12020-021-02912-w · Cited by 34
Androgens and Androgen Receptors as Determinants of Vascular Sex Differences Across the Lifespan
Lucas-Herald, A. K., & Touyz, R. M. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.09.018 · Cited by 35
Tong, S. F., Ng, C. J., Lee, B.-C., Lee, V. K. M., Khoo, E. M., Lee, E.-G., & Tan, H. M. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.178 · Cited by 34
Roles of Testosterone Replacement in Cardiac Ischemia–Reperfusion Injury
Pongkan, W., Chattipakorn, S. C., & Chattipakorn, N. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415587977 · Cited by 34
New and developing pharmacotherapy for osteoporosis in men
Gennari, L., & Bilezikian, J. P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1428559 · Cited by 34
Diagnosing and Managing Low Serum Testosterone
Rivas, A. M., Mulkey, Z., Lado‐Abeal, J., & Yarbrough, S. (2014) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2014.11929145 · Cited by 34
Sasaki, L., Hamada, Y., Yarimizu, D., Suzuki, T., Nakamura, H., Shimada, A., Pham, K. T. N., Shao, X., Yamamura, K., Inatomi, T., et al. (2022) · Nature Aging · doi:10.1038/s43587-021-00167-8 · Cited by 35
Testosterone Replacement Therapy and Mortality in Older Men
Hackett, G. I. (2015) · Drug Safety · doi:10.1007/s40264-015-0348-y · Cited by 34
Association Between Testosterone Supplementation Therapy and Thrombotic Events in Elderly Men
Ramasamy, R., Scovell, J. M., Mederos, M. A., Ren, R., Jain, L., & Lipshultz, L. I. (2015) · Urology · doi:10.1016/j.urology.2015.03.049 · Cited by 33
McGill, J., Shoskes, D. A., & Sabanegh, E. S. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12010 · Cited by 33
Male hormones and men's quality of life
Khera, M. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000256 · Cited by 33
Tsai, M., Lee, S.-M., Chen, H., & Wu, B. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.01.023 · Cited by 33
Chang, S., Biltoft, D., Skakkebaek, A. H., Fedder, J., Bojesen, A., Bor, M. V., Gravholt, C. H., & Münster, A. B. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.08.011 · Cited by 33
Correlation between sex hormone levels and obesity in the elderly male
Cao, J. J., Chen, T.-M., Hao, W., Li, J., Liu, L., Zhu, B., & Li, X. (2012) · The Aging Male · doi:10.3109/13685538.2012.666585 · Cited by 33
Testosterone Levels and Quality of Life in Diverse Male Patients With Cancers Unrelated to Androgens
Fleishman, S. B., Khan, H., Homel, P., Suhail, M. F., Strebel-Amrhein, R., Mohammad, F., Mahajan, D., Rosenwald, V., Guarino, M. J., Mirzoyev, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3818 · Cited by 34
Effects of androgens on cardiovascular remodeling
Ikeda, Y., Aihara, K., Yoshida, S., Akaike, M., & Matsumoto, T. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0126 · Cited by 33
Review of health risks of low testosterone and testosterone administration
Jia, H. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i4.338 · Cited by 33
Dalmasso, C., Patil, C. N., Cardozo, L. L. Y., Romero, D. G., & Maranon, R. O. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007074 · Cited by 33
Testosterone administration in older men
Matsumoto, A. M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.02.011 · Cited by 32
Testosterone, Cardiovascular Risk, and Hormonophobia
Morgentaler, A. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12556 · Cited by 32
Metabolic Syndrome, Testosterone, and Cardiovascular Mortality in Men
Lin, J., Lee, J., Wu, C., Caffrey, J. L., Chang, M., Hwang, J., Dowling, N. F., & Lin, Y.-S. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02343.x · Cited by 32
Testosterone, Thrombophilia, and Thrombosis
Glueck, C. J., Richardson-Royer, C., Schultz, R., Burger, T., Labitue, F., Riaz, M. K., Padda, J., Bowe, D., Goldenberg, N., & Wang, P. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029613485154 · Cited by 32
Tao, J., Liu, X., & Bai, W. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00110 · Cited by 32
Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model
Roch, P. J., Henkies, D., Carstens, J. C., Krischek, C., Lehmann, W., Komrakova, M., & Sehmisch, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.556581 · Cited by 35
EMAS position statement: Testosterone replacement therapy in older men
Kanakis, G., Pofi, R., Goulis, D. G., Isidori, A. M., Armeni, E., Erel, C. T., Fistonić, I., Hillard, T., Hirschberg, A. L., Męczekalski, B., et al. (2023) · Maturitas · doi:10.1016/j.maturitas.2023.107854 · Cited by 35
Influence of Androgens on Circulating Adiponectin in Male and Female Rodents
Yarrow, J. F., Beggs, L. A., Conover, C. F., McCoy, S. C., Beck, D. T., & Borst, S. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047315 · Cited by 33
Rosario, E. R., Aqeel, R., Brown, M. A., Sanchez, G., Moore, C., & Patterson, D. P. (2012) · Journal of Head Trauma Rehabilitation · doi:10.1097/htr.0b013e318250eac6 · Cited by 32
Treatment strategies for diabetic patients suffering from erectile dysfunction: an update
Redrow, G. P., Thompson, C. M., & Wang, R. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.934809 · Cited by 32
Metabolic syndrome and hypogonadism – two peas in a pod
Ebrahimi, F., & Christ‐Crain, M. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14283 · Cited by 32
Metadata
- Authors
- Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., Choong, K., Lakshman, K. M., Mazer, N. A., Miciek, R., Krasnoff, J., Elmi, A., Knapp, P. E., Brooks, B., Appleman, E., Aggarwal, S., Bhasin, G., Hede-Brierley, L., Bhatia, A., Collins, L., LeBrasseur, N., Fiore, L. D., & Bhasin, S.
- Affiliations
- Boston University (US)
- Brigham and Women's Hospital (US)
- New England Research Institutes (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-08
- Volume
- 363
- Issue
- 2
- Pages
- 109-122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3440621
- OpenAlex
- W2155877918
- Cited by
- 1,494
- References
- 56
- Citations by year
- 2026: 33 · 2025: 52 · 2024: 68 · 2023: 63 · 2022: 76 · 2021: 66 · 2020: 91 · 2019: 65 · 2018: 92 · 2017: 132 · 2016: 103 · 2015: 122 · 2014: 169 · 2013: 96 · 2012: 108
- FWCI
- 85.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5p30ag031679-15)
- National Institute on Aging (U01AG014369, R01AG037193, 5 P30 AG031679, P30-AG031679, 1UO1AG14369)
- National Center for Research Resources (UL1RR025771)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- testosterone replacement therapy, testosterone gel, adverse events, cardiovascular events, older men, mobility limitations, hypogonadism, muscle strength, trial discontinuation, drug safety
- MeSH terms
- Administration, Cutaneous, Aged, Aged, 80 and over, Cardiovascular Diseases, Double-Blind Method, Exercise Test, Gels, Humans, Hyperlipidemias, Hypertension, Male, Obesity, Risk Factors, Testosterone, Logistic Models, Walking, Kaplan-Meier Estimate, Muscle Strength
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
